RhumbLine Advisers’s iBio IBIO Stock Holding History

RhumbLine Advisers’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-455	Closed	-$97K	–	3158
2022 Q1	$97K	Sell	455 -55	-11%	-$11.5K	﹤0.01%	2890
2021 Q4	$140K	Sell	510 -9	-2%	-$3.43K	﹤0.01%	2899
2021 Q3	$275K	Buy	519 +15	+3%	+$9.34K	﹤0.01%	2800
2021 Q2	$381K	Buy	504 +205	+69%	+$150K	﹤0.01%	2680
2021 Q1	$230K	Buy	299 +85	+40%	+$74.1K	﹤0.01%	2796
2020 Q4	$112K	Buy	214 +121	+130%	+$98.6K	﹤0.01%	2956
2020 Q3	$95K	Buy	93 +4	+4%	+$5.8K	﹤0.01%	2877
2020 Q2	$99K	Buy	+89	New	+$58.2K	﹤0.01%	2971

Other funds holding IBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

RhumbLine Advisers's IBIO Position: Q2 2022 in Review

RhumbLine Advisers sold out of iBio (IBIO) in Q2 2022, closing a stake of 455 shares — an estimated $97K sold.

RhumbLine Advisers first reported a position in IBIO in Q2 2020 and held it in 8 quarters. The position peaked at $381K in Q2 2021. 53 funds tracked by Wall St. Rank hold IBIO as of Q2 2022.

RhumbLine Advisers reported no remaining iBio position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 455 iBio shares in Q2 2022, an estimated $97K.
RhumbLine Advisers first reported a position in iBio in Q2 2020 and held it in 8 quarters.
RhumbLine Advisers's iBio position peaked at $381K in Q2 2021.
53 funds tracked by Wall St. Rank held iBio as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.